Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Detecting cryptic clinically relevant structural variation in exome-sequencing data increases diagnostic yield for developmental disorders.

Tytuł:
Detecting cryptic clinically relevant structural variation in exome-sequencing data increases diagnostic yield for developmental disorders.
Autorzy:
Gardner EJ; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, Hinxton CB10 1SA, UK.
Sifrim A; Department of Human Genetics, KU Leuven, Herestraat 49, Box 602, Leuven 3000, Belgium.
Lindsay SJ; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, Hinxton CB10 1SA, UK.
Prigmore E; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, Hinxton CB10 1SA, UK.
Rajan D; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, Hinxton CB10 1SA, UK.
Danecek P; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, Hinxton CB10 1SA, UK.
Gallone G; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, Hinxton CB10 1SA, UK.
Eberhardt RY; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, Hinxton CB10 1SA, UK.
Martin HC; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, Hinxton CB10 1SA, UK.
Wright CF; University of Exeter Medical School, Institute of Biomedical and Clinical Science, Royal Devon and Exeter Hospital, Exeter EX2 5DW, UK.
FitzPatrick DR; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, WGH, Edinburgh EH4 2SP, UK.
Firth HV; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, Hinxton CB10 1SA, UK; East Anglian Medical Genetics Service, Box 134, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK.
Hurles ME; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, Hinxton CB10 1SA, UK. Electronic address: .
Źródło:
American journal of human genetics [Am J Hum Genet] 2021 Nov 04; Vol. 108 (11), pp. 2186-2194. Date of Electronic Publication: 2021 Oct 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: 2008- : [Cambridge, MA] : Cell Press
Original Publication: Baltimore, American Society of Human Genetics.
MeSH Terms:
Developmental Disabilities/*diagnosis
Developmental Disabilities/*genetics
Exome Sequencing/*methods
Child ; Female ; Humans ; Male ; Methyl-CpG-Binding Protein 2/genetics
References:
Genet Med. 2019 Nov;21(11):2413-2421. (PMID: 31182824)
Hum Mutat. 2017 Aug;38(8):922-931. (PMID: 28544139)
Ann Neurol. 2010 Dec;68(6):944-50. (PMID: 21154482)
Nat Biotechnol. 2020 Nov;38(11):1347-1355. (PMID: 32541955)
Genet Med. 2018 Oct;20(10):1216-1223. (PMID: 29323667)
Bioinformatics. 2010 Mar 1;26(5):589-95. (PMID: 20080505)
Nature. 2020 May;581(7809):434-443. (PMID: 32461654)
Nature. 2016 Aug 17;536(7616):285-91. (PMID: 27535533)
Genome Res. 2019 Feb;29(2):159-170. (PMID: 30587507)
Nature. 2020 Oct;586(7831):757-762. (PMID: 33057194)
Lancet. 2015 Apr 4;385(9975):1305-14. (PMID: 25529582)
Sci Data. 2016 Jun 07;3:160025. (PMID: 27271295)
Bioinformatics. 2009 Aug 15;25(16):2078-9. (PMID: 19505943)
Genome Biol. 2019 Jun 3;20(1):117. (PMID: 31159850)
Hum Mol Genet. 2018 Jul 15;27(14):2531-2545. (PMID: 29718204)
Am J Hum Genet. 2012 Oct 5;91(4):597-607. (PMID: 23040492)
Genome Res. 2017 Nov;27(11):1916-1929. (PMID: 28855259)
Genome Res. 2010 Sep;20(9):1297-303. (PMID: 20644199)
Nat Commun. 2019 May 30;10(1):2373. (PMID: 31147538)
Genet Med. 2020 May;22(5):974-978. (PMID: 31965078)
J Med Genet. 2010 Apr;47(4):242-8. (PMID: 19914908)
Bioinformatics. 2016 Apr 15;32(8):1220-2. (PMID: 26647377)
Genet Med. 2018 Oct;20(10):1122-1130. (PMID: 29446766)
Nature. 2020 May;581(7809):444-451. (PMID: 32461652)
Nat Genet. 1999 Oct;23(2):185-8. (PMID: 10508514)
Nature. 2018 Mar 29;555(7698):611-616. (PMID: 29562236)
Am J Hum Genet. 2021 May 6;108(5):919-928. (PMID: 33789087)
J Med Genet. 2001 Apr;38(4):224-8. (PMID: 11283202)
Bioinformatics. 2009 Nov 1;25(21):2865-71. (PMID: 19561018)
Genome Med. 2018 Dec 7;10(1):95. (PMID: 30526634)
Nat Commun. 2019 Oct 11;10(1):4630. (PMID: 31604926)
Brief Bioinform. 2013 Mar;14(2):178-92. (PMID: 22517427)
BMC Bioinformatics. 2009 Dec 15;10:421. (PMID: 20003500)
J Med Genet. 2006 Oct;43(10):814-6. (PMID: 16690727)
Genome Res. 2019 Jul;29(7):1047-1056. (PMID: 31227601)
Grant Information:
United Kingdom WT_ Wellcome Trust; United Kingdom DH_ Department of Health; WT098051 United Kingdom WT_ Wellcome Trust
Contributed Indexing:
Keywords: bioinformatics; developmental disorders; diagnostics; insertions/deletions; structural variation
Substance Nomenclature:
0 (MECP2 protein, human)
0 (Methyl-CpG-Binding Protein 2)
Entry Date(s):
Date Created: 20211009 Date Completed: 20211122 Latest Revision: 20221207
Update Code:
20240104
PubMed Central ID:
PMC8595893
DOI:
10.1016/j.ajhg.2021.09.010
PMID:
34626536
Czasopismo naukowe
Structural variation (SV) describes a broad class of genetic variation greater than 50 bp in size. SVs can cause a wide range of genetic diseases and are prevalent in rare developmental disorders (DDs). Individuals presenting with DDs are often referred for diagnostic testing with chromosomal microarrays (CMAs) to identify large copy-number variants (CNVs) and/or with single-gene, gene-panel, or exome sequencing (ES) to identify single-nucleotide variants, small insertions/deletions, and CNVs. However, individuals with pathogenic SVs undetectable by conventional analysis often remain undiagnosed. Consequently, we have developed the tool InDelible, which interrogates short-read sequencing data for split-read clusters characteristic of SV breakpoints. We applied InDelible to 13,438 probands with severe DDs recruited as part of the Deciphering Developmental Disorders (DDD) study and discovered 63 rare, damaging variants in genes previously associated with DDs missed by standard SNV, indel, or CNV discovery approaches. Clinical review of these 63 variants determined that about half (30/63) were plausibly pathogenic. InDelible was particularly effective at ascertaining variants between 21 and 500 bp in size and increased the total number of potentially pathogenic variants identified by DDD in this size range by 42.9%. Of particular interest were seven confirmed de novo variants in MECP2, which represent 35.0% of all de novo protein-truncating variants in MECP2 among DDD study participants. InDelible provides a framework for the discovery of pathogenic SVs that are most likely missed by standard analytical workflows and has the potential to improve the diagnostic yield of ES across a broad range of genetic diseases.
Competing Interests: Declaration of interests M.E.H. is a founder of, consultant to, director of, and holds shares in Congenica Ltd and is a consultant to the AZ Centre for Genomics Research. H.V.F. is a Section Editor for genetics for UpToDate. All other authors declare no conflict of interest.
(Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies